老虎证券
Invest
Pricing
Rewards
Support
Learn
About
Quotes
TigerAI
登录
立即注册
Toggle
美股
详情
本页面由Tiger Trade Technology Pte. Ltd.提供服务
Tvardi Therapeutics Inc
3.77
+0.0300
0.80%
成交量:
2.83万
成交额:
10.62万
市值:
3,536.77万
市盈率:
-0.48
高:
3.81
开:
3.70
低:
3.65
收:
3.74
52周最高:
43.65
52周最低:
3.50
股本:
938.13万
流通股本:
777.87万
量比:
0.69
换手率:
0.36%
股息:
- -
股息率:
- -
每股收益(TTM):
-7.8700
每股收益(LYR):
-4.5947
净资产收益率:
-135.64%
总资产收益率:
-72.68%
市净率:
1.27
市盈率(LYR):
-0.82
数据加载中...
总览
公司
新闻资讯
公告
Tvardi Therapeutics Inc 新一代STAT3抑制剂Tti-109一期临床健康受试者顶线数据预计2026年上半年公布
美股速递
·
01/08
Tvardi Therapeutics计划于2026年上半年发布Tti-101在肝细胞癌(HCC)二期试验中的主要数据
美股速递
·
2025/11/14
Tvardi Therapeutics Inc:Piper Sandler将评级从增持下调至中性,目标价从78美元下调至4美元
美股速递
·
2025/10/13
嗡嗡声--美国股票走势-Bloom Energy、Argan、Endra Life Sciences
路透中文
·
2025/10/13
嗡嗡声--美国股票走势-Bloom Energy、Argan、Endra Life Sciences
路透中文
·
2025/10/13
BUZZ-肺病药物未能达到试验目标,Tvardi Therapeutics跌停
路透中文
·
2025/10/13
Tvardi Therapeutics股价盘前暴跌66.3%,特发性肺纤维化试验未达预期目标
美股速递
·
2025/10/13
Tvardi Therapeutics Inc就特发性肺纤维化二期Revert试验初步数据提供最新进展
美股速递
·
2025/10/13
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎国际,美股交易,港股交易,交易美股,股票信息,股价,美股行情,美股打新,港股打新,IPO打新,购买美股,全球投资","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/TVRD/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"TVRD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVRD\",,,,,undefined,":{"symbol":"TVRD","market":"US","secType":"STK","nameCN":"Tvardi Therapeutics Inc","latestPrice":3.77,"timestamp":1772050457297,"preClose":3.74,"halted":0,"volume":28331,"delay":0,"changeRate":0.008021390374331498,"floatShares":7778729,"shares":9381344,"eps":-7.87,"marketStatus":"交易中","change":0.03,"latestTime":"02-25 15:14:24 EST","open":3.7,"high":3.81,"low":3.65,"amount":106172.5614905,"amplitude":0.042781,"askPrice":3.78,"askSize":176,"bidPrice":3.72,"bidSize":53,"shortable":3,"etf":0,"ttmEps":-7.87,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1772053200000},"marketStatusCode":2,"adr":0,"listingDate":1391144400000,"exchange":"NASDAQ","adjPreClose":3.74,"postHourTrading":{"tag":"盘后","latestPrice":3.74,"preClose":3.74,"latestTime":"16:10 EST","volume":6,"amount":22.44,"timestamp":1771967404381,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.692836,"impliedVol":0.061,"impliedVolPercentile":0.0431},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVRD\",,,,,undefined,":{"symbol":"TVRD","floatShares":7778729,"roa":"-72.68%","roe":"-135.64%","lyrEps":-4.594733,"volumeRatio":0.692836,"shares":9381344,"dividePrice":0,"high":3.81,"amplitude":0.042781,"preClose":3.74,"low":3.65,"week52Low":3.5,"pbRate":"1.27","week52High":43.65,"institutionHeld":0,"latestPrice":3.77,"committee":-0.537118,"eps":-7.87,"divideRate":0,"volume":28331,"delay":0,"ttmEps":-7.87,"open":3.7,"prevYearClose":4.3,"prevWeekClose":3.64,"prevMonthClose":3.97,"prevQuarterClose":4.3,"fiveDayClose":3.6,"twentyDayClose":4.31,"sixtyDayClose":4.02},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TVRD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"TVRD","fiscalQuarterEnding":"2025/09","expectedEps":-0.83,"name":null,"time":"盘后","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.59},{"market":"US","date":"2025-08-14","symbol":"TVRD","fiscalQuarterEnding":"2025/06","expectedEps":-0.51,"name":null,"time":"盘后","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":1},{"market":"US","date":"2025-05-13","symbol":"TVRD","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"post","actualEps":-3.22},{"market":"US","date":"2025-04-16","symbol":"TVRD","defaultRemindTime":1744810200000,"type":"split","dateTimestamp":1744776000000,"forFactor":3,"toFactor":1,"ratio":3},{"market":"US","date":"2025-03-11","symbol":"TVRD","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1741665600000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TVRD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TVRD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.25,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.25,"analysts":8,"updateTime":1770526800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TVRD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TVRD","date":"2026-02-24","current":-0.479034,"percent":0.944828,"low":-17.054928,"twenty":-11.769409,"median":-1.841041,"eighty":-1.57903,"high":-1.408431,"avg":-5.442227,"sd":5.233352,"marketCap":34992413},"quantilePoints":[{"date":"2025-08-01","current":-6.984237,"twenty":-7.018674,"median":-6.984237,"eighty":-6.867475,"marketCap":242869870},{"date":"2025-08-08","current":-6.220168,"twenty":-7.05634,"median":-6.986928,"eighty":-6.651705,"marketCap":216300131},{"date":"2025-08-15","current":-6.400424,"twenty":-7.003609,"median":-6.690985,"eighty":-6.397734,"marketCap":222568344},{"date":"2025-08-22","current":-10.573024,"twenty":-9.576632,"median":-6.986928,"eighty":-6.42948,"marketCap":249861702},{"date":"2025-08-29","current":-12.013447,"twenty":-10.759129,"median":-7.048807,"eighty":-6.480866,"marketCap":283901784},{"date":"2025-09-05","current":-12.078921,"twenty":-11.588463,"median":-7.134899,"eighty":-6.493511,"marketCap":285449060},{"date":"2025-09-12","current":-14.047103,"twenty":-11.928926,"median":-9.803211,"eighty":-6.612426,"marketCap":331961128},{"date":"2025-09-19","current":-15.372451,"twenty":-12.457478,"median":-10.666275,"eighty":-6.823352,"marketCap":363281754},{"date":"2025-09-26","current":-14.606606,"twenty":-13.432046,"median":-11.499578,"eighty":-6.955181,"marketCap":345183308},{"date":"2025-10-03","current":-14.82882,"twenty":-14.620891,"median":-11.737664,"eighty":-6.987466,"marketCap":350434671},{"date":"2025-10-10","current":-17.054928,"twenty":-14.850248,"median":-11.943013,"eighty":-6.991233,"marketCap":403042070},{"date":"2025-10-17","current":-2.571334,"twenty":-14.850248,"median":-11.769409,"eighty":-6.823352,"marketCap":60765765},{"date":"2025-10-24","current":-2.047544,"twenty":-14.833582,"median":-11.58886,"eighty":-6.422216,"marketCap":48387554},{"date":"2025-10-31","current":-1.849138,"twenty":-14.74787,"median":-11.130543,"eighty":-4.843171,"marketCap":43698837},{"date":"2025-11-07","current":-1.563435,"twenty":-14.662953,"median":-10.195062,"eighty":-2.595143,"marketCap":36947086},{"date":"2025-11-14","current":-1.631573,"twenty":-14.620891,"median":-9.523459,"eighty":-2.06421,"marketCap":38557323},{"date":"2025-11-21","current":-1.515552,"twenty":-14.489944,"median":-7.06764,"eighty":-1.887232,"marketCap":35836734},{"date":"2025-11-28","current":-1.634574,"twenty":-14.266143,"median":-6.990963,"eighty":-1.811838,"marketCap":38651137},{"date":"2025-12-05","current":-1.658378,"twenty":-13.805842,"median":-6.911597,"eighty":-1.667399,"marketCap":39214017},{"date":"2025-12-12","current":-1.781368,"twenty":-13.436014,"median":-6.493242,"eighty":-1.662637,"marketCap":42122234},{"date":"2025-12-19","current":-1.543324,"twenty":-13.412999,"median":-6.400424,"eighty":-1.660082,"marketCap":36493428},{"date":"2025-12-26","current":-1.5949,"twenty":-13.32332,"median":-6.349307,"eighty":-1.639335,"marketCap":37713002},{"date":"2026-01-02","current":-1.705987,"twenty":-13.031267,"median":-2.777676,"eighty":-1.642509,"marketCap":40339779},{"date":"2026-01-09","current":-1.678216,"twenty":-12.62652,"median":-2.62292,"eighty":-1.634574,"marketCap":39683085},{"date":"2026-01-16","current":-1.789303,"twenty":-12.344784,"median":-2.448323,"eighty":-1.634574,"marketCap":42309861},{"date":"2026-01-23","current":-1.91626,"twenty":-12.181298,"median":-2.07532,"eighty":-1.634574,"marketCap":45311891},{"date":"2026-01-30","current":-1.547291,"twenty":-12.091222,"median":-1.95231,"eighty":-1.634574,"marketCap":36587241},{"date":"2026-02-06","current":-1.408431,"twenty":-12.026542,"median":-1.896756,"eighty":-1.617117,"marketCap":33303771},{"date":"2026-02-13","current":-1.475877,"twenty":-11.900753,"median":-1.8627,"eighty":-1.598129,"marketCap":34898599},{"date":"2026-02-20","current":-1.424301,"twenty":-11.810677,"median":-1.847154,"eighty":-1.590139,"marketCap":33679024},{"date":"2026-02-24","current":-1.479845,"twenty":-11.769409,"median":-1.841041,"eighty":-1.57903,"marketCap":34992413}],"updateTime":1772050464739},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TVRD\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1153510288","title":"Tvardi Therapeutics Inc 新一代STAT3抑制剂Tti-109一期临床健康受试者顶线数据预计2026年上半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1153510288","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153510288?lang=zh_cn&edition=fundamental","pubTime":"2026-01-08 21:13","pubTimestamp":1767878002,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc宣布,其新一代STAT3抑制剂Tti-109的一期临床试验取得重要进展。针对健康志愿者的顶线数据收集工作正按计划推进,预计将于2026年上半年完成。\n该研究旨在评估Tti-109的安全性、耐受性及药代动力学特征。STAT3作为关键信号传导蛋白,在多种肿瘤生长中扮演核心角色。Tti-109通过精准抑制STAT3活性,为晚期癌症治疗提供了新思路。\n目前临床试验进程符合预期时间表。若数据结果达到预设终点,将为后续针对实体瘤和血液恶性肿瘤的二期研究奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"gpt_icon":0},{"id":"1175189763","title":"Tvardi Therapeutics计划于2026年上半年发布Tti-101在肝细胞癌(HCC)二期试验中的主要数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1175189763","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175189763?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 05:26","pubTimestamp":1763069193,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics计划于2026年上半年发布Tti-101在肝细胞癌(HCC)二期试验中的主要数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TVRD"],"gpt_icon":0},{"id":"1133823913","title":"Tvardi Therapeutics Inc:Piper Sandler将评级从增持下调至中性,目标价从78美元下调至4美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1133823913","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133823913?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 22:06","pubTimestamp":1760364390,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc:Piper Sandler将评级从增持下调至中性,目标价从78美元下调至4美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TVRD"],"gpt_icon":0},{"id":"2575740111","title":"嗡嗡声--美国股票走势-Bloom Energy、Argan、Endra Life Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2575740111","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575740111?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 21:14","pubTimestamp":1760361263,"startTime":"0","endTime":"0","summary":"nL3N3VU0QT ** Argan SA AGX.N:BUZZ - 在摩根大通将其评级上调至 \"增持 \"后上涨 nL6N3VU0HO ** Abeona Therapeutics Inc ABEO.O:BUZZ - 因美国 FDA 将其眼病基因疗法选入试点项目而上涨 nL3N3VU0RT ** Bicara Therapeutic Inc BCAX.O:BUZZ - 在美国 FDA 授予其癌症疗法 \"突破性 \"标签后上涨 nL3N3VU0T8 ** Endra Life Sciences Inc NDRA.O:BUZZ - 在获得490万美元融资后暴涨 nL3N3VU0TG ** Ryanair Holdings PLC RYAAY.O:BUZZ - 巴克莱继续看好廉价航空公司而非传统竞争对手。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nL3S3VU0W4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE000KEQY171.SGD","RIO.AU","NEM","STUB","LU0320765489.SGD","LU2065169927.USD","AU","LU2129689605.HKD","DVN","LU2168564065.EUR","NDRA","ALK","LU1066051498.USD","LU0949170426.SGD","LU0256863902.USD","LU2129689431.USD","LU2168564222.USD","LU1894683348.USD","RIO.UK","TVRD","LU0345780521.USD","LU0345769631.USD","AGX","LU0215105999.USD","LU0738911758.USD","COP","BE","BHP.AU","CVX","LNT","XOM","FAST","ABEO","SCCO","BYND","LU2129689514.USD","BK4533","PGEN","LU1119994496.HKD","MACW.SI","BCAX","LU2023250843.SGD"],"gpt_icon":1},{"id":"2575401114","title":"嗡嗡声--美国股票走势-Bloom Energy、Argan、Endra Life Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2575401114","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575401114?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 21:14","pubTimestamp":1760361263,"startTime":"0","endTime":"0","summary":"nL3N3VU0QT ** Argan SA AGX.N:BUZZ - 在摩根大通将其评级上调至 \"增持 \"后上涨 nL6N3VU0HO ** Abeona Therapeutics Inc ABEO.O:BUZZ - 因美国 FDA 将其眼病基因疗法选入试点项目而上涨 nL3N3VU0RT ** Bicara Therapeutic Inc BCAX.O:BUZZ - 在美国 FDA 授予其癌症疗法 \"突破性 \"标签后上涨 nL3N3VU0T8 ** Endra Life Sciences Inc NDRA.O:BUZZ - 在获得490万美元融资后暴涨 nL3N3VU0TG ** Ryanair Holdings PLC RYAAY.O:BUZZ - 巴克莱继续看好廉价航空公司而非传统竞争对手。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nL3T3VU0W4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002521.SGD","XOM","RIO.UK","ALK","COP","LU0955669360.SGD","LU0203201768.USD","SG9999015978.USD","STUB","BE","BK4008","FAST","MACW.SI","NDRA","DVN","AGX","RIO.AU","LU0417517546.SGD","PGEN","HK0000306701.USD","BCAX","LU0266512473.USD","LU0314106906.USD","BK4522","TVRD","LU0210536198.USD","LU0170899867.USD","BHP.AU","LU0889566641.SGD","LNT","CVX","IE00B19Z9P08.USD","NEM","LU1989764748.USD","AU","ABEO","IE00B7KXQ091.USD","LU1244550221.USD","LU2092627202.USD","SCCO","BYND","LU2750360641.GBP"],"gpt_icon":1},{"id":"2575405106","title":"BUZZ-肺病药物未能达到试验目标,Tvardi Therapeutics跌停","url":"https://stock-news.laohu8.com/highlight/detail?id=2575405106","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575405106?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 20:02","pubTimestamp":1760356979,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nL3T3VU0RU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TVRD"],"gpt_icon":0},{"id":"1177816248","title":"Tvardi Therapeutics股价盘前暴跌66.3%,特发性肺纤维化试验未达预期目标","url":"https://stock-news.laohu8.com/highlight/detail?id=1177816248","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177816248?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 19:49","pubTimestamp":1760356154,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics股价在盘前交易中大跌66.3%,该公司的特发性肺纤维化治疗试验未能实现预设目标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"gpt_icon":0},{"id":"1154998252","title":"Tvardi Therapeutics Inc就特发性肺纤维化二期Revert试验初步数据提供最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1154998252","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154998252?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 19:30","pubTimestamp":1760355014,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc就特发性肺纤维化二期Revert试验初步数据提供最新进展","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}]}}